Company / Total Assets
Aclaris Therapeutics, Inc. Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$160.5M
FY2025
5-year range
$160.5M / $254.6M
FY2021-FY2025
Trend
-27.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 9 years, ranging from $71M in FY2020 to $276M in FY2018.
Based on SEC 10-K filings.
$160M in FY2025 with a 5-year CAGR of +17.8%.
Declined from $197M to $160M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -14.3%
- 5-Year CAGR
- +17.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.8%, indicating consistent growth.
- In FY2025, total assets decreased 27.2% year-over-year.
- Peak total assets was recorded in FY2018.
- Lowest total assets in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $160.5M | -27.2% |
| FY2024 | $220.3M | +11.6% |
| FY2023 | $197.4M | -22.5% |
| FY2022 | $254.6M | +1.3% |
| FY2021 | $251.2M | +254.9% |
| FY2020 | $70.8M | -28.0% |
| FY2019 | $98.3M | -64.3% |
| FY2018 | $275.6M | +13.2% |
| FY2017 | $243.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026